173 related articles for article (PubMed ID: 35544190)
1. Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.
Nikayin S; Rhee TG; Cunningham ME; de Fontnouvelle CA; Ostroff RB; Sanacora G; Wilkinson ST
JAMA Psychiatry; 2022 Jul; 79(7):736-738. PubMed ID: 35544190
[TBL] [Abstract][Full Text] [Related]
2. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Gastaldon C; Papola D; Ostuzzi G; Barbui C
Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
[TBL] [Abstract][Full Text] [Related]
3. Intranasal esketamine for depression: Not so special K.
Rosenman S
Australas Psychiatry; 2022 Aug; 30(4):533-534. PubMed ID: 35491953
[TBL] [Abstract][Full Text] [Related]
4. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
[TBL] [Abstract][Full Text] [Related]
5. Esketamine for treatment resistant depression.
Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
[No Abstract] [Full Text] [Related]
6. Esketamine (Spravato) for Treatment-Resistant Depression.
Jalloh M
Am Fam Physician; 2020 Mar; 101(6):339-340. PubMed ID: 32163257
[No Abstract] [Full Text] [Related]
7. Esketamine as a treatment for paediatric depression: questions of safety and efficacy.
Zimmermann KS; Richardson R; Baker KD
Lancet Psychiatry; 2020 Oct; 7(10):827-829. PubMed ID: 31952957
[No Abstract] [Full Text] [Related]
8. Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression.
Harris E
JAMA; 2023 Nov; 330(17):1611. PubMed ID: 37851473
[No Abstract] [Full Text] [Related]
9. Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.
McIntyre RS
Am J Psychiatry; 2021 Dec; 178(12):1130-1132. PubMed ID: 34855455
[No Abstract] [Full Text] [Related]
10. Esketamine for resistant depression in older people with cognitive impairment: A case report.
Romani S; Jacquet B; Cohen D; Curiale V; Laurent I; Louchart De La Chapelle S
Encephale; 2023 Dec; 49(6):651-653. PubMed ID: 37604711
[No Abstract] [Full Text] [Related]
11. Is Intravenous Ketamine Better Than Intranasal Esketamine for Treating Treatment-Resistant Depression?
Mansuri Z; Shah B; Yadav G; Kamil SH; Kainth T; Srinivas S; Patel H; Reddy A; Bachu A
Prim Care Companion CNS Disord; 2024 Feb; 26(1):. PubMed ID: 38382071
[No Abstract] [Full Text] [Related]
12. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
13. The Future of Ketamine in the Treatment of Teen Depression.
Parikh T; Walkup JT
Am J Psychiatry; 2021 Apr; 178(4):288-289. PubMed ID: 33789452
[No Abstract] [Full Text] [Related]
14. Augmentation in depression: Esketamine, a new standard?
Rosenblat JD; McIntyre RS
Med; 2023 Dec; 4(12):852-854. PubMed ID: 38070477
[TBL] [Abstract][Full Text] [Related]
15. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
[No Abstract] [Full Text] [Related]
16. Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
Bahji A; Vazquez GH; Zarate CA
J Affect Disord; 2021 Mar; 282():258-260. PubMed ID: 33418376
[No Abstract] [Full Text] [Related]
17. Esketamine clinical trials: reply to Maju
Gastaldon C; Papola D; Ostuzzi G; Barbui C
Epidemiol Psychiatr Sci; 2020 Apr; 29():e122. PubMed ID: 32345395
[TBL] [Abstract][Full Text] [Related]
18. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
20. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G
Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
